Bacteriophage therapy and infective endocarditis – is it realistic?

Abstract

Infective endocarditis (IE) is a severe infection of the inner heart. Even with current standard treatment, the mean in‐hospital mortality is as high as 15–20%, and 1‐year mortality is up to 40% for left‐sided IE. Importantly, IE mortality rates have not changed substantially over the past 30 years, and the incidence of IE is rising. The treatment is challenging due to the bacterial biofilm mode of growth inside the heart valve vegetations, resulting in antibiotic tolerance. Achieving sufficient antibiotic anti‐biofilm concentrations in the biofilms of the heart valve vegetations is problematic, even with high‐dose and long‐term antibiotic therapy. The increasing prevalence of IE caused by antibiotic‐resistant bacteria adds to the challenge. Therefore, adjunctive antibiotic‐potentiating drug candidates and strategies are increasingly being investigated. Bacteriophage therapy is a reemerging antibacterial treatment strategy for difficult‐to‐treat infections, mainly biofilm‐associated and caused by multidrug‐resistant bacteria. However, significant knowledge gaps regarding the safety and efficacy of phage therapy impede more widespread implementation in clinical practice. Hopefully, future preclinical and clinical testing will reveal whether it is a viable treatment. The objective of the present review is to assess whether bacteriophage therapy is a realistic treatment for IE.